Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | HTR5A | P47898 | 2/20 | 0.32 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688661 | 0.83 | PTPN1 (0.32) | PTPN1PTPN6PTPN11SMN1; SMN2 | |
| SCHEMBL691794 | 0.77 | CUL4A (0.43) | HTR5ACUL4A | |
| SCHEMBL11689202 | 0.76 | CD44 (0.42) | PTPN1PTPN6PTPN11SMN1; SMN2 | |
| SCHEMBL30089434 | 0.76 | CD44 (0.42) | PTPN1PTPN6PTPN11SMN1; SMN2 | |
| SCHEMBL2783567 | 0.76 | CES2 (0.38) | TAAR1CES2CES1 | |
| SCHEMBL31285235 | 0.76 | CES2 (0.38) | TAAR1CES2CES1 | |
| SCHEMBL114436 | 0.75 | — | — | |
| SCHEMBL29409495 | 0.75 | — | — | |
| SCHEMBL31081959 | 0.74 | TSHR (0.39) | TAAR1 | |
| SCHEMBL113475 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189863-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | PULMOCIDE LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-10189863-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | PULMOCIDE LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| EP-3204388-B1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LTD (GB) | 2018-12-12 | — | — | EP | disclosed |
| US-20170355717-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355717-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355717-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| EP-3204388-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | Pulmocide Limited (GB) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055792-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055792-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189863-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | AZI2, HRH4, ZC3HAV1 | TAAR1 3061/4885HTR5A 35/4885CUL4A 521/4885 |
| US-20170355717-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | ZC3HAV1, DHX15, AZI2 | TAAR1 2850/4885HTR5A 31/4885CUL4A 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.